Evidence map›Paper›PMID 38383302›Full record

ArticleBMC pulmonary medicine2024

Case report of a novel alpha1-antitrypsin null variant in Türkiye: Q0

Dilek Karadoğan, Ünal Şahin, Bettina Dreger, Laura Grandoso, Lourdes Osaba

Open access · goldAbstract readCase Reports
In one paragraph

Article in BMC pulmonary medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Dilek KaradoğanSchool of Medicine, Department of Chest Diseases, Recep Tayyip Erdoğan University, Rize, Türkiye. cakmakcidilek@yahoo.com.ORCID http://orcid.org/0000-0001-5321-3964
Ünal ŞahinSchool of Medicine, Department of Chest Diseases, Recep Tayyip Erdoğan University, Rize, Türkiye.ORCID http://orcid.org/0000-0003-1836-6193
Bettina DregerPulmonology Medical Affairs, Grifols Deutschland GmbH, Frankfurt, Germany.
Laura GrandosoProgenika Biopharma, a Grifols company, Derio, Spain.
Lourdes OsabaProgenika Biopharma, a Grifols company, Derio, Spain.
Grifols (Spain) · ESRecep Tayyip Erdoğan University · TRGrifols (Germany) · DE

Funding

Grifols NA
6 · The paper itself

Abstract

backgroundAlpha1-antitrypsin (AAT) is a serine protease inhibitor that serves as a counterbalance to the activity of elastases, e.g., neutrophil elastase in lung tissue. AAT deficiency (AATD) is a rare disorder usually arising from mutations to the SERPINA1 gene that codes for AAT. The most common AATD alleles are S and Z which produce ~ 40% and ~ 90% reductions in serum AAT, respectively. Rare genetic variants (> 500 identified) can also be associated with mild to severe AATD.

resultsThis report describes a novel mutation of SERPINA1 producing AATD, which we have designated, Q0

conclusionsAlthough many SERPINA1 variants have been identified, variants with large deletions and identified in a homozygous individual, as seen in this case with Q0

Indexed as

alpha 1-Antitrypsin DeficiencyAdultalpha 1-AntitrypsinFemaleHomozygoteHumansLungSequence DeletionTurkeyalpha 1-AntitrypsinAlpha1-antitrypsinAlpha1-antitrypsin deficiencyEmphysemaSERPINA1

Identifiers

PMID38383302
PMCPMC10882785
OpenAlexW4391995773

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.